Ocugen Inc. said on Monday the COVID-19 vaccine developed by its Indian partner Bharat Biotech International Ltd. met the main goals of a trial in the United States.
https://www.pharmalive.com/wp-content/uploads/2021/11/Indian-home-grown-COVID-19-shot-wins-WHO-emergency-use-approval-Reuters-11-3-21-1.jpeg183275Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-01-09 06:59:442023-01-09 11:30:54Ocugen-Bharat Biotech COVID vaccine meets main goals in U.S. trial
